Curcumin-based nanoformulations as an emerging therapeutic strategy for inflammatory lung diseases

Future Medicinal ChemistryVol. 15, No. 7 EditorialCurcumin-based nanoformulations as an emerging therapeutic strategy for inflammatory lung diseasesAsif Ahmad Bhat, Riya Thapa, Ahsas Goyal, Vetriselvan Subramaniyan, Deepak Kumar, Saurabh Gupta, Sachin Kumar Singh, Kamal Dua & Gaurav GuptaAsif Ahmad Bhat https://orcid.org/0000-0003-4346-8319School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Mahal Road, Jaipur, India, Riya Thapa https://orcid.org/0000-0001-9271-5756School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Mahal Road, Jaipur, India, Ahsas Goyal https://orcid.org/0000-0003-0110-9238Institute of Pharmaceutical Research, GLA University, Mathura, U.P., India, Vetriselvan Subramaniyan https://orcid.org/0000-0002-3488-7311Pharmacology Unit, Jeffrey Cheah School of Medicine and Health Sciences, Jalan Lagoon Selatan, Bandar Sunway 47500 Selangor Darul Ehsan, Monash University, Malaysia, Deepak Kumar https://orcid.org/0000-0003-2241-0054Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan, 173229, India, Saurabh Gupta https://orcid.org/0000-0002-4783-0293Chameli Devi Institute of Pharmacy, Department of Pharmacology, Khandwa Road, Village Umrikheda, Near Toll booth, Indore, Madhya Pradesh, 452020, India, Sachin Kumar Singh https://orcid.org/0000-0003-3823-6572School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, IndiaFaculty of Health, Australian Research Centre in Complementary & Integrative Medicine, University of Technology, Sydney, Ultimo-NSW, 2007, Australia, Kamal Dua https://orcid.org/0000-0002-7507-1159Faculty of Health, Australian Research Centre in Complementary & Integrative Medicine, University of Technology, Sydney, Ultimo-NSW, 2007, AustraliaDiscipline of Pharmacy, Graduate School of Health, University of Technology, Sydney, Ultimo-NSW, 2007, Australia & Gaurav Gupta *Author for correspondence: E-mail Address: gauravpharma25@gmail.comhttps://orcid.org/0000-0001-7941-0229School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Mahal Road, Jaipur, IndiaUttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, 248007, IndiaPublished Online:4 May 2023https://doi.org/10.4155/fmc-2023-0048AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleReferences1. Alharbi KS, Afzal O, Almalki WH et al. Nuclear factor-kappa B (NF-κB) inhibition as a therapeutic target for plant nutraceuticals in mitigating inflammatory lung diseases. Chem. Biol. Interact. 354, 109842 (2022).Crossref, Medline, CAS, Google Scholar2. Satija S, Mehta M, Gupta G, Chellappan DK, Dua K. Targeting interleukins in chronic airway diseases using advanced drug delivery. Future Med. Chem. 12(20), 1805–1807 (2020).Link, CAS, Google Scholar3. Prasher P, Sharma M, Chellappan DK et al. Advanced drug delivery systems targeting NF-κB in respiratory diseases. Future Med. Chem. 13(13), 1087–1090 (2021).Link, CAS, Google Scholar4. Chan Y, Mehta M, Paudel KR et al. Versatility of liquid crystalline nanoparticles in inflammatory lung diseases. Nanomedicine 16(18), 1545–1548 (2021).Crossref, Medline, CAS, Google Scholar5. Chellappan DK, Hansbro PM, Dua K et al. Vesicular systems containing curcumin and their applications in respiratory disorders – a mini review. Pharm. Nanotechnol. 5(4), 250–254 (2017).Medline, CAS, Google Scholar6. Chellappan DK, Ng ZY, Wong JY et al. Immunological axis of curcumin-loaded vesicular drug delivery systems. Future Med. Chem. 10(8), 839–844 (2018).Link, CAS, Google Scholar7. Awasthi A, Kumar B, Gulati M et al. Novel nanostructured lipid carriers co-loaded with mesalamine and curcumin: formulation, optimization and in vitro evaluation. Pharm. Res. 39(11), 2817–2829 (2022).Crossref, Medline, CAS, Google Scholar8. Sharma A, Hawthorne S, Jha SK et al. Effects of curcumin-loaded poly(lactic-co-glycolic acid) nanoparticles in MDA-MB231 human breast cancer cells. Nanomedicine 16(20), 1763–1773 (2021).Crossref, Medline, CAS, Google Scholar9. Zhong W, Zhang X, Zeng Y, Lin D, Wu J. Recent applications and strategies in nanotechnology for lung diseases. Nano Res. 14(7), 2067–2089 (2021).Crossref, Medline, CAS, Google Scholar10. Wang W, Zhu R, Xie Q et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int. J. Nanomedicine 7, 3667–3677 (2012).Crossref, Medline, CAS, Google Scholar11. Evans CE. Hypoxia-inducible factor signaling in inflammatory lung injury and repair. Cells 11(2), 183 (2022).Crossref, Medline, CAS, Google Scholar12. Alhusaini A, Alhumaidan S, Almogren R, Alsaif S, Alsultan E, Hussein I. Nano-curcumin protects against sodium nitrite–induced lung hypoxia through modulation of mitogen-activated protein kinases/c-Jun NH2-terminal kinase signaling pathway. Dose Response 19(3), 15593258211033148 (2021).Crossref, Google Scholar13. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid. Redox Signal. 20(7), 1126–1167 (2014).Crossref, Medline, CAS, Google Scholar14. Yuan R, Li Y, Han S et al. Fe–curcumin nanozyme-mediated reactive oxygen species scavenging and anti-inflammation for acute lung injury. ACS Cent. Sci. 8(1), 10–21 (2022).Crossref, Medline, CAS, Google Scholar15. Piao C, Zhuang C, Kang M, Oh J, Lee M. Pulmonary delivery of curcumin-loaded glycyrrhizic acid nanoparticles for anti-inflammatory therapy. Biomater. Sci. 10(23), 6698–6706 (2022).Crossref, Medline, CAS, Google Scholar16. Yen F-L, Tsai M-H, Yang C-M et al. Curcumin nanoparticles ameliorate ICAM-1 expression in TNF-α-treated lung epithelial cells through p47 phox and MAPKs/AP-1 pathways. PLOS ONE 8(5), e63845 (2013).Crossref, Medline, CAS, Google Scholar17. Valizadeh H, Abdolmohammadi-Vahid S, Danshina S et al. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int. Immunopharmacol. 89, 107088 (2020).Crossref, Medline, CAS, Google Scholar18. Asadirad A, Nashibi R, Khodadadi A et al. Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial. Phytother. Res. 36(2), 1023–1031 (2022).Crossref, Medline, CAS, Google Scholar19. Hassaniazad M, Eftekhar E, Inchehsablagh BR et al. A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients. Phytother. Res. 35(11), 6417–6427 (2021).Crossref, Medline, CAS, Google Scholar20. Li Y, Guo C, Chen Q et al. Improvement of pneumonia by curcumin-loaded bionanosystems based on Platycodon grandiflorum polysaccharides via calming cytokine storm. Int. J. Biol. Macromol. 202, 691–706 (2022).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 15, No. 7 STAY CONNECTED Metrics Downloaded 20 times History Received 18 February 2023 Accepted 24 February 2023 Published online 4 May 2023 Published in print April 2023 Information© 2023 Newlands PressFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download